124 related articles for article (PubMed ID: 38857264)
21. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.
Wang Z; Schmidt F; Weisblum Y; Muecksch F; Barnes CO; Finkin S; Schaefer-Babajew D; Cipolla M; Gaebler C; Lieberman JA; Oliveira TY; Yang Z; Abernathy ME; Huey-Tubman KE; Hurley A; Turroja M; West KA; Gordon K; Millard KG; Ramos V; Da Silva J; Xu J; Colbert RA; Patel R; Dizon J; Unson-O'Brien C; Shimeliovich I; Gazumyan A; Caskey M; Bjorkman PJ; Casellas R; Hatziioannou T; Bieniasz PD; Nussenzweig MC
Nature; 2021 Apr; 592(7855):616-622. PubMed ID: 33567448
[TBL] [Abstract][Full Text] [Related]
22. A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primates.
Liu Z; Zhou J; Wang X; Xu W; Teng Z; Chen H; Chen M; Zhang G; Wang Y; Huang J; Wang Q; Jiang S; Lu L
Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2221713120. PubMed ID: 36897979
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial.
Bennett C; Woo W; Bloch M; Cheung K; Griffin P; Mohan R; Deshmukh S; Arya M; Cumming O; Neville AM; McCallum Pardey TG; Plested JS; Cloney-Clark S; Zhu M; Kalkeri R; Patel N; Marcheschi A; Swan J; Smith G; Cho I; Glenn GM; Walker R; Mallory RM;
Lancet Infect Dis; 2024 Jun; 24(6):581-593. PubMed ID: 38460525
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
Elife; 2022 Jan; 11():. PubMed ID: 35072628
[TBL] [Abstract][Full Text] [Related]
25. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
[TBL] [Abstract][Full Text] [Related]
26. Imprinting of serum neutralizing antibodies by Wuhan-1 mRNA vaccines.
Liang CY; Raju S; Liu Z; Li Y; Asthagiri Arunkumar G; Case JB; Scheaffer SM; Zost SJ; Acreman CM; Gagne M; Andrew SF; Carvalho Dos Anjos DC; Foulds KE; McLellan JS; Crowe JE; Douek DC; Whelan SPJ; Elbashir SM; Edwards DK; Diamond MS
Nature; 2024 Jun; 630(8018):950-960. PubMed ID: 38749479
[TBL] [Abstract][Full Text] [Related]
27. Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies.
Jette CA; Cohen AA; Gnanapragasam PNP; Muecksch F; Lee YE; Huey-Tubman KE; Schmidt F; Hatziioannou T; Bieniasz PD; Nussenzweig MC; West AP; Keeffe JR; Bjorkman PJ; Barnes CO
Cell Rep; 2021 Sep; 36(13):109760. PubMed ID: 34534459
[TBL] [Abstract][Full Text] [Related]
28. SARS-CoV-2 Omicron boosting induces de novo B cell response in humans.
Alsoussi WB; Malladi SK; Zhou JQ; Liu Z; Ying B; Kim W; Schmitz AJ; Lei T; Horvath SC; Sturtz AJ; McIntire KM; Evavold B; Han F; Scheaffer SM; Fox IF; Mirza SF; Parra-Rodriguez L; Nachbagauer R; Nestorova B; Chalkias S; Farnsworth CW; Klebert MK; Pusic I; Strnad BS; Middleton WD; Teefey SA; Whelan SPJ; Diamond MS; Paris R; O'Halloran JA; Presti RM; Turner JS; Ellebedy AH
Nature; 2023 May; 617(7961):592-598. PubMed ID: 37011668
[TBL] [Abstract][Full Text] [Related]
29. Follow-Up and Comparative Assessment of SARS-CoV-2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA-1273 Heterologous Booster Vaccination.
Younes S; Nicolai E; Pieri M; Bernardini S; Daas HI; Al-Sadeq DW; Younes N; Shurrab FM; Nizamuddin PB; Humaira F; Al-Dewik N; Yassine HM; Abu-Raddad LJ; Ismail A; Nasrallah GK
Influenza Other Respir Viruses; 2024 May; 18(5):e13290. PubMed ID: 38706402
[TBL] [Abstract][Full Text] [Related]
30. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.
Yuan M; Chen X; Zhu Y; Dong X; Liu Y; Qian Z; Ye L; Liu P
J Virol; 2022 Aug; 96(16):e0077522. PubMed ID: 35916510
[TBL] [Abstract][Full Text] [Related]
31. Epitopes of an antibody that neutralizes a wide range of SARS-CoV-2 variants in a conserved subdomain 1 of the spike protein.
Ishimaru H; Nishimura M; Shigematsu H; Marini MI; Hasegawa N; Takamiya R; Iwata S; Mori Y
J Virol; 2024 May; 98(5):e0041624. PubMed ID: 38624232
[TBL] [Abstract][Full Text] [Related]
32. Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster.
Favresse J; Gillot C; Cabo J; David C; Dogné JM; Douxfils J
Int J Infect Dis; 2024 Jun; 143():107028. PubMed ID: 38583825
[TBL] [Abstract][Full Text] [Related]
33. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection.
Wang Z; Muecksch F; Schaefer-Babajew D; Finkin S; Viant C; Gaebler C; Hoffmann HH; Barnes CO; Cipolla M; Ramos V; Oliveira TY; Cho A; Schmidt F; Da Silva J; Bednarski E; Aguado L; Yee J; Daga M; Turroja M; Millard KG; Jankovic M; Gazumyan A; Zhao Z; Rice CM; Bieniasz PD; Caskey M; Hatziioannou T; Nussenzweig MC
Nature; 2021 Jul; 595(7867):426-431. PubMed ID: 34126625
[TBL] [Abstract][Full Text] [Related]
34. Immunity against Delta and Omicron variants elicited by homologous inactivated vaccine booster in kidney transplant recipients.
Zhang L; Yang J; Lai C; Wan L; Xiong S; Kong W; Liu Z; Yu P; Chen M; Mai W; Khan SA; Deng M; Chen L; Lei Y; Zhou Q; Yu N; Li P; Chen Z; Ji T
Front Immunol; 2022; 13():1042784. PubMed ID: 36700230
[TBL] [Abstract][Full Text] [Related]
35. Sequential immunization with SARS-CoV-2 RBD vaccine induces potent and broad neutralization against variants in mice.
Song S; Zhou B; Cheng L; Liu W; Fan Q; Ge X; Peng H; Fu YX; Ju B; Zhang Z
Virol J; 2022 Jan; 19(1):2. PubMed ID: 34983583
[TBL] [Abstract][Full Text] [Related]
36. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.
Arunachalam PS; Walls AC; Golden N; Atyeo C; Fischinger S; Li C; Aye P; Navarro MJ; Lai L; Edara VV; Röltgen K; Rogers K; Shirreff L; Ferrell DE; Wrenn S; Pettie D; Kraft JC; Miranda MC; Kepl E; Sydeman C; Brunette N; Murphy M; Fiala B; Carter L; White AG; Trisal M; Hsieh CL; Russell-Lodrigue K; Monjure C; Dufour J; Spencer S; Doyle-Meyers L; Bohm RP; Maness NJ; Roy C; Plante JA; Plante KS; Zhu A; Gorman MJ; Shin S; Shen X; Fontenot J; Gupta S; O'Hagan DT; Van Der Most R; Rappuoli R; Coffman RL; Novack D; McLellan JS; Subramaniam S; Montefiori D; Boyd SD; Flynn JL; Alter G; Villinger F; Kleanthous H; Rappaport J; Suthar MS; King NP; Veesler D; Pulendran B
Nature; 2021 Jun; 594(7862):253-258. PubMed ID: 33873199
[TBL] [Abstract][Full Text] [Related]
37. Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines.
Bowen JE; Addetia A; Dang HV; Stewart C; Brown JT; Sharkey WK; Sprouse KR; Walls AC; Mazzitelli IG; Logue JK; Franko NM; Czudnochowski N; Powell AE; Dellota E; Ahmed K; Ansari AS; Cameroni E; Gori A; Bandera A; Posavad CM; Dan JM; Zhang Z; Weiskopf D; Sette A; Crotty S; Iqbal NT; Corti D; Geffner J; Snell G; Grifantini R; Chu HY; Veesler D
Science; 2022 Aug; 377(6608):890-894. PubMed ID: 35857529
[TBL] [Abstract][Full Text] [Related]
38. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
[TBL] [Abstract][Full Text] [Related]
39. Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2.
Huang KA; Chen X; Mohapatra A; Nguyen HTV; Schimanski L; Tan TK; Rijal P; Vester SK; Hills RA; Howarth M; Keeffe JR; Cohen AA; Kakutani LM; Wu YM; Shahed-Al-Mahmud M; Chou YC; Bjorkman PJ; Townsend AR; Ma C
Nat Commun; 2023 Jan; 14(1):311. PubMed ID: 36658148
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity and safety of COVID-19 booster vaccination: A population-based clinical trial to identify the best vaccination strategy.
Sieghart D; Hana CA; Dürrschmid C; Heinz LX; Haslacher H; Zlesak M; Piccini G; Manenti A; Montomoli E; Jorda A; Fedrizzi C; Hasenoehrl T; Zdravkovic A; Anderle K; Wiedermann U; Drapalik S; Steinbrecher H; Bergmann F; Firbas C; Jordakieva G; Wagner B; Leonardi M; Pierleoni G; Ballini M; Benincasa L; Marchi S; Trombetta C; Perkmann T; Crevenna R; Zeitlinger M; Bonelli M; Aletaha D; Radner H
J Clin Virol; 2024 Aug; 173():105661. PubMed ID: 38503118
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
